Evidence map›Paper›PMID 40894120›Full record

ArticlemedRxiv : the preprint server for health sciences2025

IDH1-dependent m6A methylation defines transcriptomic heterogeneity in glioma.

Syeda Maheen Batool, Hanna Lee, Koushik Muralidharan, Saad Murtaza Khan, Ana K Escobedo, Denalda Gashi, Kesli Faber, Emil Ekanayake, Tiffaney Hsia, Yana Al-Inaya and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Syeda Maheen BatoolDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hanna LeeDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Koushik MuralidharanDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Saad Murtaza KhanDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ana K EscobedoDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Denalda GashiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0009-0004-3751-6075
Kesli FaberDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Emil EkanayakeDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Tiffaney HsiaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Yana Al-InayaDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Aishwarya KosgiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Julie J MillerTranslational Neuro-Oncology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Daniel P CahillDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Gavin P DunnDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Bryan D ChoiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Allegra S PettiDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Bob S CarterDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Leonora BalajDepartment of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0931-9715

Funding

Imaging and Liquid Biopsy for Glioma Diagnosis and Treatment MonitoringR01CA239078 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI BALAJ, LEONORA, LEE, HAKHO · 2020 to 2024
$3.1M
Standardized Molecular Analyses of Glioma EVsR01CA237500 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CARTER, BOB S, LEE, HAKHO · 2020 to 2024
$3.0M
Molecular subtyping of brain tumors using a blood-based multiplexed assayR01CA291826 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Leonora Balaj, Bob S Carter · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA237500NCI NIH HHS R01 CA239078NCI NIH HHS R01 CA291826
6 · The paper itself

Abstract

Gliomas are biologically heterogeneous brain tumors with marked differences in clinical behavior based on the IDH1 mutation status. While epigenetic dysregulation is well characterized, the contribution of RNA modifications, particularly N6-methyladenosine (m6A), remains underexplored. Using direct RNA nanopore sequencing of patient-derived gliomas, we generated the first isoform-resolved m6A maps across IDH1-mutant and wild-type tumors. IDH1-mutant gliomas exhibited globally elevated m6A methylation, along with increased expression of methyltransferases (METTL3, METTL14) and stabilizing readers (YTHDF3). In contrast, wild-type glioblastomas showed enhanced expression of m6A erasers (ALKBH5, FTO) and RNA decay factors (YTHDF2). These subtype-specific differences in m6A architecture impacted transcript stability, isoform usage, and gene expression. Isoform-level analyses revealed stronger prognostic associations than gene-level parameter, including for IGF2BP2-202, PUF60-202, and GLUL-203. Our study establishes m6A as a critical, subtype-specific layer of RNA regulation in glioma with clinical and therapeutic implications.

Indexed as

gliomaIDH1isoformsN6-methyladenosine

Identifiers

PMID40894120
PMCPMC12393588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.